In his official tour, the Cuban president learned about AICA´s projects and difficulties to move on.
Antonio Vallin, AICA director, told the Cuban leader about the center´s possibilities of becoming a High-Tech Company and also about workers´ wage.
AICA Pharmaceutical Laboratories, belonging to BioCubaFarma, have 180 products in its market portfolio, manufacturing the vaccine candidate Abdala, Mambisa and Nasalferon, all produced by Cuban scientists.
Meanwhile, the Neuroscience Center is working on manufacturing new lines for nasopharyngeal masks and swabs.
pgh/Pll/oda / ebr/gdc